Internet-based Video-conferencing to Address Alcohol Use and Pain: a Pilot Trial

Sponsor
Boston University Charles River Campus (Other)
Overall Status
Recruiting
CT.gov ID
NCT04441593
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH)
48
2
2
20.2
24
1.2

Study Details

Study Description

Brief Summary

This pilot study seeks to provide effect size estimates and test feasibility of a novel, integrated behavioral approach to reduce heavy drinking and chronic pain among patients in HIV-care delivered via internet-based videoconferencing.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)
  • Behavioral: Treatment as Usual
N/A

Detailed Description

This pilot study is a between-groups design to compare a novel integrated behavioral video telehealth intervention for heavy drinking PLWH with chronic pain to a control condition. Forty-eight heavy drinking patients in HIV-care with moderate or greater pain will be recruited for the study. Following baseline assessment, participants will be randomly assigned to either intervention or control conditions. Participants will complete assessment measures of heavy drinking and pain interference/severity at 3 and 6 months post-baseline. Secondary alcohol outcomes will include alcohol-related consequences

Study Design

Study Type:
Interventional
Anticipated Enrollment :
48 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Compare Intervention to Control Condition in a Between Subjects DesignCompare Intervention to Control Condition in a Between Subjects Design
Masking:
Single (Outcomes Assessor)
Masking Description:
Three and six month assessments will be conducted by RA who is masked to intervention condition
Primary Purpose:
Treatment
Official Title:
Internet-based Videoconferencing to Address Alcohol Use and Pain Among People With HIV
Actual Study Start Date :
Dec 23, 2020
Anticipated Primary Completion Date :
Mar 30, 2022
Anticipated Study Completion Date :
Aug 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Videoconferencing Intervention for Heavy Drinking and Chronic Pain

Behavioral: Motivational and Cognitive-Behavioral Management for Alcohol and Pain (MCBMAP)
Videoconferencing intervention to reduce alcohol use and chronic pain interference and severity
Other Names:
  • Intervention
  • Active Comparator: Control

    Treatment as Usual

    Behavioral: Treatment as Usual
    Psychoeducation and Information about Treatment Resources
    Other Names:
  • Control
  • Outcome Measures

    Primary Outcome Measures

    1. Alcohol Time Line Follow-Back (30)- Heavy Drinking Episodes [Past 30 days]

      Number of heavy drinking episodes NIAAA criteria (5+drinks men/ 4+ drinks women)

    2. Alcohol Time Line Follow-Back (30) - Average Drinks per Week [Past 30 days]

      Average number of standard alcohol-containing drinks in the past 30 days

    3. Brief Pain Inventory - Pain Severity [Past 7 days]

      BPI is an 11-point scale anchored with "0" best and "10" is worst Scale range 0-10

    4. Brief Pain Inventory - Pain Interference [Past 7-Days]

      BPI is an 11-point scale anchored with "0" best and "10" is worst Scale range 0-10. Pain Interference is measured as the mean of 7-items each rated on an 11-point scale

    Secondary Outcome Measures

    1. Short Inventory of Alcohol Problems-Revised [3 months]

      17-item measure with 4-point Likert scale items ranging from "0" never to "3" daily/almost daily. Scale range 0-51

    2. Goal Systems Assessment Battery-Alcohol [Past 30 days]

      Ratings of self-regulatory capacities related to reducing alcohol use. Items are 5-point Likert-scales. There are 4 subscales utilized including planning, monitoring, self-efficacy, and value. Higher scores indicate better outcomes

    3. Goal Systems Assessment Battery-Pain [Past 30 days]

      Ratings of self-regulatory capacities related to reducing alcohol use. Items are 5-point Likert-scales. There are 4 subscales utilized including planning, monitoring, self-efficacy, and value. Higher scores indicate better outcomes

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • engaged in HIV care, heavy drinking defined as more than 7/14 drinks per week for women/men or by a single episode of 4/5 (women/men), chronic (at least 3 months duration) moderate or greater (4 or more on the severity scale of the BPI, and non-cancer related pain
    Exclusion Criteria:
    • psychoactive medication for pain or alcohol use for fewer than 2 months

    • history of bipolar disorder or schizophrenia

    • current expressed suicidal intent

    • prior history of alcohol withdrawal related seizures or delirium tremens

    • current behavioral treatment for pain or alcohol use

    • any scheduled surgery within the next 6 months or acute life threatening illness that requires treatment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Boston University Department of Psychological and Brain Sciences Boston Massachusetts United States 02215
    2 General Clinical Research Unit, Boston University Boston Massachusetts United States 02215

    Sponsors and Collaborators

    • Boston University Charles River Campus
    • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Boston University Charles River Campus
    ClinicalTrials.gov Identifier:
    NCT04441593
    Other Study ID Numbers:
    • 4546 [Study 3]
    • UH3AA026192
    First Posted:
    Jun 22, 2020
    Last Update Posted:
    Jan 5, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 5, 2021